Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Bluecross ADC Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 5.01.582

    Antibody-Drug Conjugate Coverage

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.582 alerts

    Get alerted when Policy 5.01.582 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical-necessity coverage and prior authorization for specified antibody-drug conjugates used to treat hematologic and solid malignancies under the medical benefit.

    Policy Summary
    PayerPremera Bluecross
    PolicyAntibody-Drug Conjugate Coverage
    Policy CodePolicy 5.01.582
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit medical records documenting that medical-necessity criteria are met, including the diagnosis, relevant history, physical evaluation, and medication history.
    SourceLink
    POLICY UPDATE CHANGES

    Updated Padcev criteria to include combination therapy with pembrolizumab and berahyaluronidase alfa-pmph for locally advanced or metastatic urothelial cancer.

    Removed the requirement that individuals receiving Padcev for muscle-invasive bladder cancer be ineligible for cisplatin-containing chemotherapy.

    Added Datroway coverage criteria for triple-negative breast cancer.

    Added Datroway coverage criteria for locally advanced or metastatic EGFR-mutated non-small-cell lung cancer.

    Added Emrelis coverage criteria for locally advanced or metastatic non-squamous non-small-cell lung cancer with high c-Met protein overexpression.

    Added coverage criteria for Datroway.

    Moved Adcetris and Polivy from policy 2.03.502 to this antibody-drug conjugate policy.

    Updated Besponsa age eligibility from 18 years to 1 year or older.

    Expanded Mylotarg coverage for newly diagnosed CD33-positive acute myeloid leukemia.

    Added Zynlonta for relapsed or refractory large B-cell lymphoma.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    9Antibody-drug conjugates with listed coverage criteria
    Up to 6 monthsInitial authorization for most listed drugs
    Up to 12 monthsReauthorization for most listed drugs
    InvestigationalOther uses
    2026Most recent clinical update year

    Coverage Criteria

    Adcetris initial therapy

    Covered when at least one of the following indications applies:

    Adcetris indications

    • Previously untreated stage III or IV classical Hodgkin lymphoma, in combination with chemotherapy
    • Pediatric high-risk classical Hodgkin lymphoma: Age 2 years to less than 22 years; previously untreated high-risk classical Hodgkin lymphoma, defined as Ann Arbor stage IIB with bulk disease, stage IIIB, stage IVA, or stage IVB; used in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (AVE-PC)Age 2 to <22 years
    • Post-auto-HSCT consolidation: Classical Hodgkin lymphoma at high risk of relapse or progression, as post-autologous hematopoietic stem cell transplantation consolidation
    • Post-treatment classical Hodgkin lymphoma: Classical Hodgkin lymphoma after failure of autologous hematopoietic stem cell transplantation or after failure of at least two prior multi-agent chemotherapy regimens in an individual who is not an autologous hematopoietic stem cell transplantation candidate>=2 prior multi-agent regimens
    • Previously untreated CD30-positive lymphoma: Previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphoma, including angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified, in combination with chemotherapy
    • Systemic anaplastic large cell lymphoma after chemotherapy: Systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen>=1 prior multi-agent regimen
    • Primary cutaneous anaplastic large cell lymphoma or CD30-positive mycosis fungoides: Primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides after prior systemic therapy
    • Relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified, diffuse large B-cell lymphoma arising from indolent lymphoma, or high-grade B-cell lymphoma, after two or more lines of systemic therapy; the individual is not eligible for autologous hematopoietic stem cell transplantation or CAR T-cell therapy; used with lenalidomide and a rituximab product>=2 lines of systemic therapy

    Besponsa initial therapy

    Covered when all of the following are met:

    Besponsa criteria

    • Age: The individual is aged 1 year or older>=1 year
    • Diagnosis: Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia

    Datroway initial therapy

    Covered when all criteria for at least one applicable indication are met:

    Datroway indications

    • HR-positive, HER2-negative breast cancer: Age 18 years or older; unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer; prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease; prescribed by or in consultation with an oncologistAge >=18 years

      HER2-negative means IHC 0, IHC 1+, or IHC 2+/ISH-negative

    • Triple-negative breast cancer: Age 18 years or older; unresectable or metastatic triple-negative breast cancer; not a candidate for PD-1 or PD-L1 inhibitor therapy; prescribed by or in consultation with an oncologistAge >=18 years
    • EGFR-mutated NSCLC: Age 18 years or older; locally advanced or metastatic EGFR-mutated non-small-cell lung cancer; prior EGFR-directed therapy and platinum-based chemotherapy; prescribed by or in consultation with an oncologist

    Elahere initial therapy

    Covered when all of the following are met:

    Elahere criteria

    • Age: The individual is aged 18 years or older>=18 years
    • Diagnosis: Folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
    • Prior treatment: Received one or more prior systemic treatment regimens>=1 prior systemic regimen

    Emrelis initial therapy

    Covered when all of the following are met:

    Emrelis criteria

    • Age: The individual is aged 18 years or older>=18 years
    • Diagnosis: Locally advanced or metastatic non-squamous non-small-cell lung cancer
    • Biomarker: Tumor demonstrates high c-Met protein overexpression>=50% of tumor cells with strong (3+) staining by immunohistochemistry
    • Prior treatment:

    Mylotarg initial therapy

    Covered when at least one of the following indications applies:

    Mylotarg indications

    • Newly diagnosed AML: Newly diagnosed CD33-positive acute myeloid leukemia in an adult or pediatric individual aged 1 month or olderPediatric age >=1 month
    • Relapsed or refractory AML: Relapsed or refractory CD33-positive acute myeloid leukemia in an adult or pediatric individual aged 2 years or olderPediatric age >=2 years

    Padcev initial therapy

    Covered when at least one of the following indications applies:

    Padcev indications

    • Muscle-invasive bladder cancer: Age 18 years or older; Padcev is used with pembrolizumab or pembrolizumab plus berahyaluronidase alfa-pmph as neoadjuvant treatment and then continued after cystectomy as adjuvant treatmentAge >=18 years
    • Locally advanced or metastatic urothelial cancer

      • Single-agent pathway for cisplatin-ineligible disease: Age 18 years or older; ineligible for cisplatin-containing chemotherapy; previously received one or more prior lines of therapyAge >=18 years; >=1 prior line
      • Single-agent pathway after prior immunotherapy and platinum chemotherapy:

    Polivy initial therapy

    Covered when at least one of the following indications applies:

    Polivy indications

    • Previously untreated DLBCL or HGBL: Adult with previously untreated diffuse large B-cell lymphoma not otherwise specified or high-grade B-cell lymphoma; used with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP)IPI score >=2

      International Prognostic Index score must be 2 or greater

    • Relapsed or refractory DLBCL: Adult with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified; used with bendamustine and a rituximab product
    • Bridging therapy: Used as bridging therapy before anti-CD19 CAR T-cell therapy

    Tivdak initial therapy

    Covered when all of the following are met:

    Tivdak criteria

    • Age: The individual is aged 18 years or older>=18 years
    • Diagnosis: Recurrent or metastatic cervical cancer
    • Prior treatment response or progression: Disease progression on or after chemotherapy

    Zynlonta initial therapy

    Covered when all of the following are met:

    Zynlonta criteria

    • Age: The individual is aged 18 years or older>=18 years
    • Diagnosis: Relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified, diffuse large B-cell lymphoma arising from low-grade lymphoma, or high-grade B-cell lymphoma
    • Prior treatment: Received two or more lines of systemic therapy>=2 lines of systemic therapy

    Continuation therapy

    For reauthorization, all of the following are required:

    Continuation criteria

    • Drug-specific criteria: The applicable drug-specific coverage criteria continue to be met
    • Clinical response: Chart notes demonstrate that the individual continues to show a positive clinical response to therapy

      Besponsa and Mylotarg may be approved for up to 6 months; Adcetris, Datroway, Elahere, Emrelis, Padcev, Polivy, Tivdak, and Zynlonta may be approved for up to 12 months

    Padcev updated indications

    Padcev may be covered for either of the following updated indications:

    • Locally advanced or metastatic urothelial cancer: Used in combination with pembrolizumab and berahyaluronidase alfa-pmph for locally advanced or metastatic urothelial cancer
    • Muscle-invasive bladder cancer: Adult individual with muscle-invasive bladder cancer; used in combination with pembrolizumab or pembrolizumab plus berahyaluronidase alfa-pmph as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment

      The current update removed the requirement that the individual be ineligible for cisplatin-containing chemotherapy

    Datroway triple-negative breast cancer

    Covered when both of the following are met:

    • Diagnosis: Adult individual with unresectable or metastatic triple-negative breast cancer
    • Immunotherapy eligibility: The individual is not a candidate for PD-1 or PD-L1 inhibitor therapy

    Emrelis non-squamous NSCLC

    Covered when both of the following are met:

    • Diagnosis: Locally advanced or metastatic non-squamous non-small-cell lung cancer
    • Biomarker: Tumor demonstrates high c-Met protein overexpression>=50% of tumor cells with strong (3+) staining by immunohistochemistry

    Uses of the medications listed in this policy that are not identified as medically necessary are considered investigational.

    This medical policy does not apply to Medicare Advantage. Coverage remains subject to the limits and conditions of the member’s benefit plan; providers should consult the member benefit booklet or contact member services to confirm applicable coverage.

    Coding and Clinical Thresholds

    HCPCS C codesHCPCS
    C9174Injection, datopotamab deruxtecan-dlnk (Datroway), 1 mg (code termed 10/01/25)
    C9306Injection, telisotuzumab vedotin-tllv (Emrelis), 1 mg (code termed 01/01/26)
    HCPCS J codesHCPCS
    J9011Injection, datopotamab deruxtecan-dlnk (Datroway), 1 mg (new code effective 10/01/25)
    J9042Injection, brentuximab vedotin (Adcetris), 1 mg
    J9063Injection, mirvetuximab soravtansine-gynx (Elahere), 1 mg
    J9177Injection, enfortumab vedotin-ejfv (Padcev), 0.25 mg
    J9203Injection, gemtuzumab ozogamicin (Mylotarg), 0.1 mg
    J9229Injection, inotuzumab ozogamicin (Besponsa), 0.1 mg
    J9273Injection, tisotumab vedotin-tftv, (Tivdak) 1 mg
    J9309Injection, polatuzumab vedotin-piiq (Polivy), 1 mg
    J9326Injection, telisotuzumab vedotin-tllv, 1 mg (new code effective 01/01/26)
    J9359Injection, loncastuximab tesirine-lpyl, (Zynlonta) 0.075 mg
    HCPCS codes referenced in policy historyHCPCS
    J9229
    J3490
    J3590
    C9084
    J9177
    J9273
    J9359
    C9146
    J9063
    J9042
    1–10 of 15
    1/2
    Emrelis c-Met expression
    ThresholdAt least 50% of tumor cells
    Staining intensityStrong (3+) staining
    Testing methodImmunohistochemistry (IHC)
    Polivy International Prognostic Index
    Required scoreInternational Prognostic Index (IPI) score of 2 or greater
    Disease contextPreviously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified, or high-grade B-cell lymphoma

    Provider Requirements and Action Items

    Prior Authorization

    Medical-Benefit Prior Authorization

    These drugs are managed through the medical benefit and require applicable medical-benefit prior authorization before administration. Confirm authorization and benefit administration requirements before treatment.

    Note

    Verify Member Benefit Coverage

    Verify that the member's benefit covers the requested drug and service before treatment. Consult the member benefit booklet or contact Member Services regarding applicable coverage limitations.

    Note

    Follow FDA Prescribing Information

    Administer each medication according to the product's current U.S. Food and Drug Administration (FDA) dosage and administration prescribing information.

    Antibody-Drug Conjugate Background

    Antibody-drug conjugates (ADCs) combine a monoclonal antibody directed at an antigen on malignant cells with a cytotoxic payload. After the antibody binds to and is internalized by the target cell, the payload is released and may cause microtubule disruption, DNA damage, or DNA crosslinking, with the aim of targeting cancer cells while limiting exposure to nearby healthy tissue.

    Definitions

    Antibody
    TypeA blood protein
    TargetLinks to a molecule called an antigen
    Cell associationThe antigen is located on an unhealthy cell
    Monoclonal antibody
    ProductionProduced in a laboratory
    TargetDesigned to link to antigens
    Cancer-cell targetingThe antigens are usually found in high numbers on cancer cells

    Initial Therapy Criteria

    Adcetris

    Adcetris is covered only when at least one specified lymphoma indication and its required combination or treatment history applies:

    Adcetris indications: One of the listed classical Hodgkin lymphoma, systemic anaplastic large cell lymphoma, other CD30-expressing peripheral T-cell lymphoma, primary cutaneous anaplastic large cell lymphoma, CD30-expressing mycosis fungoides, or relapsed/refractory large B-cell lymphoma indications applies

    Initial authorization

    Initial authorization requires that the individual meet all applicable medical-necessity criteria for the requested drug and indication.

    Drug-specific initial therapy: The individual meets the drug-specific criteria for the requested antibody-drug conjugate and indication, including the requirements for Besponsa, Datroway, Elahere, Emrelis, Mylotarg, Padcev, Polivy, Tivdak, or Zynlonta

    Refer to the applicable drug-specific criteria above for diagnosis, age, biomarker, prior-treatment, combination, and prescriber requirements

    Continuation and Reauthorization

    Reauthorization

    Reauthorization requires both continued eligibility and documented benefit:

    • Continued eligibility: The applicable drug-specific coverage criteria continue to be met
    • Positive clinical response: Chart notes demonstrate that the individual continues to show a positive clinical response to therapy

      Besponsa and Mylotarg may be approved up to 6 months; the other listed drugs may be approved up to 12 months

    Policy Summary
    PayerPremera Bluecross
    PolicyAntibody-Drug Conjugate Coverage
    Policy CodePolicy 5.01.582
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit medical records documenting that medical-necessity criteria are met, including the diagnosis, relevant history, physical evaluation, and medication history.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Requirements and Action ItemsAntibody-Drug Conjugate BackgroundDefinitionsInitial Therapy CriteriaContinuation and Reauthorization
    Age >=18 years

    Examples of EGFR-directed therapy include afatinib, gefitinib, and osimertinib; platinum-based chemotherapy examples include cisplatin, carboplatin, and oxaliplatin

    Received one or more lines of systemic therapy
    >=1 systemic-therapy line
  1. Prescriber: Prescribed by or in consultation with an oncologist
  2. Age 18 years or older; previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy
    Age >=18 years
  3. Combination pathway: Used in combination with pembrolizumab or pembrolizumab plus berahyaluronidase alfa-pmph
  4. Treatment combination
    Used with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP)
    Documentation Required

    Submit Clinical Records

    Submit medical records supporting medical necessity for the requested treatment. Records should demonstrate that the applicable coverage criteria are met.

    • Include office visit notes documenting the diagnosis, relevant history, physical evaluation, and medication history.
    Documentation Required

    Document Ongoing Positive Response

    For reauthorization, submit chart notes demonstrating that the individual continues to show a positive clinical response to therapy and continues to meet the drug-specific coverage criteria.

    Denial Risk

    Unlisted Uses Are Investigational

    Uses of the medications outside the specified coverage criteria are considered investigational and may not be covered.

    Denial Risk

    No Documented Response May Affect Reauthorization

    Reauthorization may be denied when the submitted documentation does not show that the individual continues to have a positive clinical response to therapy.

    Prior Authorization

    Confirm Padcev MIBC Criteria

    For Padcev treatment of muscle-invasive bladder cancer (MIBC), confirm that the patient meets the updated indication and treatment requirements before requesting coverage.

    • Adult patients with MIBC may receive Padcev with pembrolizumab or pembrolizumab plus berahyaluronidase alfa-pmph as neoadjuvant treatment, continued after cystectomy as adjuvant treatment.
    • The September 2026 update removed the requirement that the individual be ineligible for cisplatin-containing chemotherapy.
    Prior Authorization

    Verify Datroway TNBC Eligibility

    For Datroway treatment of triple-negative breast cancer (TNBC), verify that the individual meets the updated eligibility requirement regarding PD-1/PD-L1 inhibitor therapy.

    • The indication applies to adults with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.
    Prior Authorization

    Document High c-Met Overexpression for Emrelis

    For Emrelis treatment of non-squamous non-small cell lung cancer (NSCLC), document the required biomarker finding before requesting coverage.

    • The indication applies to locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression.
    Antibody-drug conjugate
    Antibody componentA monoclonal antibody that finds or targets cancer cells
    Payload componentA chemotherapy drug or cytotoxic payload
    Release mechanismThe payload is released after cellular uptake
    HER2-negative
    BiomarkerHuman epidermal growth factor receptor 2 (HER2) status
    HER2-negative resultIHC 0 or IHC 1+
    Equivocal IHC resultIHC 2+ with in situ hybridization (ISH)-negative status
    High c-Met protein overexpression
    DefinitionAt least 50% of tumor cells demonstrate high c-Met protein overexpression
    StainingStrong (3+) staining
    Assessment methodImmunohistochemistry (IHC)
    Antibody-drug conjugate (ADC)
    Therapy typeA targeted antibody-drug therapy
    Targeting componentA monoclonal or tumor-directed antibody
    Cytotoxic componentA chemotherapy drug or cytotoxic payload linked to the antibody
    DLBCL
    AbbreviationDLBCL
    Full nameDiffuse large B-cell lymphoma
    Disease categoryA large B-cell lymphoma referenced in relapsed or refractory treatment criteria
    RC and PLND
    RCRadical cystectomy
    PLNDPelvic lymph node dissection
    Combined procedureRadical cystectomy with pelvic lymph node dissection
    Zynlonta
    ProductZynlonta (loncastuximab tesirine-lpyl)
    TargetCD19-directed antibody
    Payload classAlkylating agent
    Elahere
    ProductElahere (mirvetuximab soravtansine-gynx)
    TargetFolate receptor alpha (FRα)-directed antibody
    Payload classMicrotubule inhibitor